AGGRESSIVE LUNG ADENOCARCINOMA PRESENTING WITH EXTENSIVE LYMPHADENOPATHY MIMICKING LYMPHOMA: A DIAGNOSTIC CHALLENGE

Main Article Content

Elvando Tunggul Mauliate Simatupang
Elcia Melisa Dwisari Simatupang
Sri Melati Munir
Andreas Makmur
Ina Farida Rangkuti
Desfrina Kasuma
Sutoyo Eliandy

Keywords

Abstract

Micropapillary adenocarcinoma represents uncommon but highly aggressive variant of non-small cell lung cancer (NSCLC), identified for a tendency for early micro metastasis, especially to mediastinal and extra thoracic lymph nodes. The report presents a case of a 61-year-old male diagnosed with lung adenocarcinoma, characterised by rapid clinical progression. The patient experienced two hospitalisations, with a diagnostic process that was both prolonged and complex. Initially, a suspected right lung mass was identified, which was subsequently reevaluated as a potential lymphoma. After three weeks of initial admission, the patient exhibited getting worse clinical and radiological signs, including superior vena cava syndrome (SVCS), requiring emergency intervention before a confirmed cancer diagnosis. Despite the performance of both bronchoscopy and an excisional biopsy of supraclavicular lymphadenopathy, a definitive diagnosis was not accomplished. Lung adenocarcinoma was eventually confirmed after two procedures of histopathological evaluation of fine-needle aspiration biopsy (FNAB) specimens. The patient's condition got worse, lead to death shortly after diagnosis, prior to the administration of chemotherapy. This case highlights the significant effects of diagnostic delay in aggressive lung cancer subtypes, emphasising the necessity of early identification and prompt treatment to enhance prognosis and survival outcomes.

Abstract 98 | Pdf Downloads 76

References


1. Zhao Y, Shi W, Tang Q. An eleven-gene risk model associated with lymph node metastasis predicts overall survival in lung adenocarcinoma. Sci Rep. 2023 Dec 1;13(1):[page numbers if available]. Available from: https://pubmed.ncbi.nlm.nih.gov/37100777/
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
3. Sun J, Wu S, Jin Z, Ren S, Cho WC, Zhu C, et al. Lymph node micrometastasis in non–small cell lung cancer. Biomed Pharmacother. 2022;149:112817. doi:10.1016/j.biopha.2022.112817
4. Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35(1):75–91.
5. Park JK, Kim JJ, Moon SW, Lee KY. Lymph node involvement according to lung adenocarcinoma subtypes: lymph node involvement is influenced by lung adenocarcinoma subtypes. J Thorac Dis. 2017;9(10):3903–10.
6. Yu Y, Jian H, Shen L, Zhu L, Lu S. Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: a study of 2268 cases. Eur J Surg Oncol. 2016;42(11):1714–9.
7. Zhang W, Mu G, Huang J, Bian C, Wang H, Gu Y, et al. Lymph node metastasis and its risk factors in T1 lung adenocarcinoma. Thorac Cancer. 2023;14(30):2993–3000.
8. Chen B, Wang X, Yu X, Xia WJ, Zhao H, Li XF, et al. Lymph node metastasis in Chinese patients with clinical T1 non-small cell lung cancer: a multicenter real-world observational study. Thorac Cancer. 2019;10(3):533–42.
9. Zhang C, Pang G, Ma C, Wu J, Wang P, Wang K. Preoperative risk assessment of lymph node metastasis in cT1 lung cancer: a retrospective study from Eastern China. J Immunol Res. 2019;2019:Article ID 7456914. doi:10.1155/2019/7456914
10. Chen B, Xia W, Wang Z, Zhao H, Li X, Liu L, et al. Risk analyses of N2 lymph-node metastases in patients with T1 non-small cell lung cancer: a multi-center real-world observational study in China. J Cancer Res Clin Oncol. 2019;145(11):2771–7. doi:10.1007/s00432-019-03006-x
11. Kanchustambham V, Saladi S. Adenocarcinoma of the lung with inguinal lymph node metastasis. Cureus. 2021;13(3):e13701. doi:10.7759/cureus.13701
12. Sun G, Sun Y, Zou Z, Xu S. Analysis of segmental lymph node metastasis and clinical features in cT1N0M0 lung adenocarcinoma. Biomed Res Int. 2020;2020:8149140. doi:10.1155/2020/ 8149140
13. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022. J Natl Compr Canc Netw. 2022;20(5):497–530. doi:10.6004/jnccn.2022. 0012
14. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, et al. Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small cell lung cancer. Clin Lung Cancer. 2017;18(3):e197–204. doi:10.1016/j.cllc.2017.05.015